X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARS has designed and developed neffy® to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, rapidly administered, and reliable nasal spray device for the treatment of Type I severe allergic reactions , including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 08, 2022
Details:
ARS designed neffy to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, and reliable nasal spray device. With its needle-free administration, neffy may help eliminate the anxiety and hesitation associated with using an autoinjector.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 21, 2022
Details:
SBT6050 is the first of a new class of targeted immuno-oncology agents designed to direct a TLR8 agonist linker-payload to activate myeloid cells in tumors expressing moderate to high levels of HER2.
Lead Product(s): SBT6050,Pembrolizumab
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
SBT8230 comprises a TLR8 agonist conjugated to an antibody specific for the liver-restricted receptor ASGR1 and is designed to promote functional cures in chronic HBV (cHBV) through potent activation of an anti-viral immune response in a liver-localized manner.
Lead Product(s): SBT8230
Therapeutic Area: Infections and Infectious Diseases Product Name: SBT8230
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Silverback Therapeutics' lead candidate SBT6050 is currently in a Phase 1/1b clinical trial for advanced or metastatic HER2-expressing solid tumors, with an update on interim data from the Phase 1 dose-escalation cohorts expected in the 2H21.
Lead Product(s): SBT6050
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2020
Details:
Silverback will present a trial-in-progress update on SBT6050-101, a Phase 1/1b dose-escalation and expansion clinical trial in patients with advanced or metastatic HER2-expressing solid tumors.
Lead Product(s): SBT6050,Pembrolizumab
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Silverback intends to use the proceeds to support its clinical development of SBT6050, a TLR8 agonist conjugated to a HER2-directed antibody currently in a Phase 1 clinical study for the treatment of HER2-expressing solid tumors, and to advance other ImmunoTAC therapeutics.
Lead Product(s): SBT6050
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 23, 2020
Details:
Comapny has started dosing in Phase 1 clinical study, a multicenter, dose escalation and expansion cohort study that will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SBT6050 in adults with HER2-expressing solid tumors.
Lead Product(s): SBT6050
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The presentation shows that TLR8 agonism potently and uniquely activates human myeloid cells, driving a broad spectrum of anti-tumor immune mechanisms, including those not dependent on T cells.
Lead Product(s): SBT6050
Therapeutic Area: Oncology Product Name: SBT6050
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Data presented shows that SBT6050 potently activates human myeloid cells in a HER2 dependent manner in vitro, and that an SBT6050 mouse surrogate exhibits potent anti-tumor efficacy as a single agent and in combination with trastuzumab in vivo.
Lead Product(s): SBT6050,Trastuzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
